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 To demonstrate non-inferiority of BF-200 ALA compared to MAL cream for the
treatment of non-aggressive basal cell carcinoma (BCC) with PDT.
 To evaluate the safety related to BF-200 ALA for treatment of non-aggressive BCC
with PDT.
 To evaluate the effect of PDT on different BCC subtypes.
 
 
Key words 
Basal cell carcinoma, 5-aminolaevulinic acid, methyl-aminolevulinate, photodynamic 
therapy, BF-RhodoLED 
 
Conflicts of interest 
C.A.M. is a board member of Euro-PDT. He has been a member of advisory boards for
Almirall, Biofrontera, Galderma, and Leo Pharma and has received speaker honoraria from
Biofrontera and Galderma.
T.D. has received lecture fees from Almirall, Biofrontera, Galderma, Leo, Meda, Riemser,
Janssen and is a member of advisory boards for Almirall, Biofrontera, Leo Pharma, Meda,
Novartis, Riemser, Janssen and has received unrestricted grants from Meda and Galderma.
A.H. has received lecture fees from Almirall-Hermal.
U.R. has been a member of advisory boards for Almirall, Biofrontera, Galderma, and Leo
Pharma; he has received speakers’ honoraria from the aforementioned companies.
R.A. is a member of the advisory board for Biofrontera and holds lectures for Biofrontera,
Galderma, and Leo Pharma.
M.U. is stakeholder in CMB Collegium Medicum Berlin GmbH; he received lecture fees
from Almirall, Biofrontera, Galderma, Leo Pharma, Mavig GmbH, and Michelson
Diagnostics.
S.I. has received travel expenses and honoraria from Galderma and Spirit HC.
R.O. is Vice Chairman of the BVDD-Regional Association North Rhine and Board
Member for Germany in the EADV. He is member of advisory boards for Novartis, Leo
Pharma, and in the past for Biofrontera; he has received speakers’ honoraria from Aspen,
Lilly, Novartis, and Biofrontera.
C.B. has been member of advisory boards for Almirall-Hermal, Biofrontera, Galderma,
ISDIN, and Leo Pharma and has received speakers´ honoraria from Almirall-Hermal,
Galderma, and Leo Pharma.
D.G. has been a member of the advisory board and received speakers’ honoraria from
Almirall, Allergan, Bayer, Galderma, Leo Pharma, Novartis, Meda, and l’Òreal.
H.J.S. is auditor of the German Cancer Society (DKG) for German skin cancer centres.
M.S. has received honoraria from Abbvie, Leo Pharma, Novartis, Janssen-Cilag, Lilly,
Hexal, Celgene, Galderma, Böhringer Ingelheim, Almirall, Sanofi, Regeneron,
Organobalance, Pfizer, GSK, Dr. Reddys, Mundipharma, and Medac.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
H.S. has received lecture fees from Biofrontera and Galderma. 
G.G. has been a member of advisory boards for Abbvie, Almirall, Leo Pharma, Meda, and 
Novartis and has received speakers’ honoraria from Abbvie, Galderma, Leo Pharma, and 
Meda. 
I.Z. is employee of Clinipace-Accovion GmbH, the company that was responsible as 
Clinical Research Organization for study conduct.  
B.S., A.G., and H.L. are employees of the sponsoring company, Biofrontera Bioscience 
GmbH and developed the study design together with the coordinating investigators. 
R.M.S. is Vice President of EURO-PDT. He has been member of advisory boards for 
Almirall, Biofrontera, Galderma, ISDIN, Leo Pharma, photonamic, and Pierre-Fabre; he 
has received speakers’ honoraria.  
R.D., P.R., S.K., S.E.B., H.M.O., V.J., H.K., and F.H. have no conflict of interest to 
declare. 
 
 
Funding source 
The study was sponsored by Biofrontera Bioscience GmbH. 
 
 
What’s already known about this topic? 
 Photodynamic therapy (PDT) using BF-200 ALA gel is registered and highly 
effective in the treatment of mild to moderate actinic keratosis and field cancerisation. 
BF-200 ALA gel was recently approved for the treatment of superficial and/or 
nodular basal cell carcinoma unsuitable for surgical treatment. 
 PDT using MAL cream is approved for the treatment of thin or non-hyperkeratotic 
and non-pigmented actinic keratoses, Bowen’s disease, and superficial and nodular 
basal cell carcinomas (BCC) when other therapies are considered less appropriate. 
 
 
What does this study add? 
 BF-200 ALA-PDT is confirmed to be significantly non-inferior to MAL-PDT for the 
treatment of non-aggressive BCC.  
 Treatment-emergent adverse events were comparable between the two patient groups, 
with similar or slightly lower recurrence rates for BF-200 ALA gel compared to MAL 
cream after 12 months. 
 
Abstract 
 
Background 
Basal cell carcinoma (BCC) represents the most common non-melanoma skin cancer 
worldwide affecting mainly adult, fair-skinned individuals. The WHO distinguishes 
aggressive and non-aggressive forms of which prototypical variants of the latter are primary 
nodular and superficial BCC. 
Objectives 
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To demonstrate non-inferiority of BF-200 ALA (a nanoemulsion gel containing 5-
aminolaevulinic acid) compared to MAL (a cream containing methyl-aminolevulinate) in the 
treatment of non-aggressive BCC with photodynamic therapy (PDT). Non-inferiority of the 
primary efficacy variable (overall patient complete response 12 weeks after last PDT) would 
be declared if the mean response for BF-200 ALA was no worse than that for MAL, within a 
statistical margin of Δ = -15%. 
Patients/Methods 
The study was a randomized, phase III trial performed in Germany and the UK with ongoing 
5-year follow-up. Of 281 randomized patients, 138 were treated with BF-200 ALA, 143 with 
MAL. Patients received two PDT sessions one week apart. Remaining lesions 12 weeks after 
the second PDT were retreated. Illumination was performed with a red light source (635 nm, 
37 J/cm
2
). Results shown include clinical endpoints as well as patients’ reassessment 12 
months after the last PDT. 
Results 
Of the BF-200 ALA-treated patients, 93.4% were complete responders compared to 91.8% in 
the MAL group. The difference of means was 1.6 with a one-sided 97.5% CI of -6.5, 
establishing non-inferiority (p<0.0001). Results for secondary efficacy parameters were in 
line with the primary outcome. Recurrence rates 12 months after the last treatment were ≤ 
10%.  
Conclusions 
Treatment of non-aggressive BCC with BF-200 ALA-PDT is highly effective and well 
tolerated with proven non-inferiority to MAL-PDT and demonstrates low recurrence rates 
after 1-year follow-up.  
EudraCT number: 2013-003241-42 
 
Introduction  
Basal cell carcinoma (BCC) represents the most common type of non-melanoma skin cancer 
(NMSC) worldwide, affecting mainly adult (age ≥40), fair-skinned individuals 1,2. Its 
incidence increases steadily and is currently estimated at 3-10% 
1,3
. In the US, a 50% increase 
in males and a 20% increase in females was observed between two observational studies in 
1977/78 and 1998/99, respectively 
4
. In Europe, incidence rates increased 3-fold between 
1997 and 2008 and rates are presumed to continue growing 
5,6
. Worldwide, the highest 
incidences were reported for Australia showing a 4.4-fold increase in NMSC between 1985 
and 2011 with higher rates in males and for BCCs, respectively 
7
. The life time risk of 
developing BCC is estimated at ~30% which increases to ~40% within 3 years in patients 
with a prior BCC 
2,6
. The aging population, higher awareness along with more frequent 
diagnosis of skin tumours, and changes in lifestyle are thought to contribute to the 
dramatically increasing numbers of patients and the associated increase in cost 
6
. New 
therapeutic options are thus in the best interest of the general public 
3
. 
Although invasive procedures are most widely used for the treatment of BCC, guideline 
recommendations are variable 
5
. Cryosurgery has a weaker recommendation whereas surgical 
excision is usually the most appropriate treatment of BCC 
1,5,8,9
. Nevertheless, alternative 
therapeutic concepts must be considered to overcome the drawbacks associated with physical 
measures, notably cosmetic outcome, functional impairments and/or the need for 
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reconstructive surgery after the treatment of multiple or larger lesions. This holds particularly 
true for locations in the face or on the neck, where at least 75% of all BCCs are located 
3,6,10
. 
Among topical therapies, photodynamic therapy (PDT) is considered appropriate for the 
treatment of low-risk tumours, such as superficial (s)BCC and nodular (n)BCC, and for the 
treatment of large or multiple lesions 
11-20
. The advantages of PDT include excellent 
compliance, and short treatment and down time, besides its high efficacy and superior 
cosmetic results.  
BF-200 ALA is a topically applied nanoemulsion-based gel that contains 7.8% 
5-aminolevulinic acid (ALA). The formulation improves ALA stability and enhances 
epidermal penetration compared to other formulations 
21,22
. Thus, the concentration of the 
active substance could be significantly reduced. In the reported clinical study, BF-200 ALA 
was compared to a cream containing 16% methyl-aminolevulinic acid (MAL) using a non-
inferiority trial design. MAL is approved for the treatment of sBCC and/or nBCC unsuitable 
for other available therapies due to possible treatment related morbidity and poor cosmetic 
outcome. Clinical studies comparing MAL with surgery or cryotherapy revealed lesion 
complete response rates for MAL ranging between 73% - 97%, always with superior 
cosmetic outcome 
20,23-25
. Both, ALA and MAL are essential prodrugs for the targeted photo-
destruction of neoplastic cells. They selectively induce accumulation of the photosensitive 
metabolite protoporphyrin IX (PpIX) due to these cells’ altered metabolism. Illumination at 
an appropriate wavelength activates PpIX and leads to the specific destruction of tumour cells 
by reactive oxygen species 
26-28
.  
A previous BCC study using a preliminary ALA nanoemulsion formulation showed a 
promising complete lesion response rate in superficial (s)BCC of 85% 6 months after a single 
PDT 
29
 confirming the results of the abovementioned studies. In order to compare BF-200 
ALA gel and MAL cream in the treatment of non-aggressive BCC, a study based on the 
exception that BF-200 ALA gel is non-inferior to MAL cream (with a non-inferiority margin 
of Δ = -15) was designed. Meanwhile, BF-200 ALA was granted a label extension for the 
treatment of superficial and nodular BCC in the EU. 
 
Material and Methods  
The study was performed as a randomized, non-inferiority, phase III trial using BF-200 ALA 
gel and MAL cream at a ratio of 1:1.  
The 24 study centres in Germany and UK included university hospitals, dermatological 
clinical centres and private dermatological practises. The study was approved by the 
responsible ethics committees and the competent authorities prior to the start of the study and 
performed according to the national drug laws, the guidelines of Good Clinical Practice and 
the Declaration of Helsinki (EudraCT number: 2013-003241-42). The study was sponsored 
by Biofrontera Bioscience GmbH. The study design was developed by the coordinating 
investigators in cooperation with the sponsor. 
 
Study medication and illumination 
The study medication was produced and released for the clinical study according to Good 
Manufacturing Practice and relevant regulations. Tubes with either BF-200 ALA gel 
(Ameluz
®
, Biofrontera, Leverkusen, Germany) or MAL cream (Metvix
®
/Metvixia
®
, 
Galderma, Lausanne, Switzerland) were used in its marketed 2 g formulations. For 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
illumination, an LED light source (BF-RhodoLED
®
, Biofrontera, Leverkusen, Germany) 
producing red light at 635 ± 9 nm was used 
30
.  
 
Study population 
Male and female subjects (>18 years of age) diagnosed with 1 to 3 non-aggressive BCC (0.5 -
 2 cm in diameter) on the face/scalp, neck/trunk, or extremities were enrolled. A 3 mm punch 
biopsy taken at screening from each target lesion had to prove eligibility of non-
aggressiveness and a thickness ≤ 2 mm by histological assessment.  
Patients with porphyria and photodermatoses as well as any intolerance to ingredients of 
BF-200 ALA gel or MAL cream were excluded. Topical treatments possibly affecting the 
response to the study treatment were not allowed during the 12 weeks preceding the first PDT 
or during the study, with the exception of topical corticosteroids. Starting the use of 
substances with phototoxic or photoallergic potential was forbidden from 8 weeks prior to 
and during PDT. Patients exposed to these medications for longer than 8 weeks were allowed 
to participate if no phototoxic or photoallergic reactions were observed. Systemic treatments 
possibly impairing the outcome were not allowed 1 - 6 months before (timeframe depending 
on the substance) and during the study; patients were allowed to take up to 100 mg 
acetylsalicylic acid daily for preventive measures. 
 
Randomization 
The randomization schedule(s) was generated by Accovion GmbH (Eschborn, Germany) 
using a validated program that automates the random assignment of treatments to 
randomization numbers. Randomization was performed with a block size of 6. Patient 
assignment to a group occurred according to the randomization schedule. 
 
Treatment protocol  
The study was conducted using an observer-blind design, as the drug products display 
different consistencies in their formulation. The treatment regimen included one obligatory 
PDT cycle with two PDT sessions 1 week apart, and a second PDT cycle in case of remaining 
lesions 12 weeks after the first cycle. The clinical observation period lasted up to 12 weeks 
after the last PDT, followed by post-treatment observation for 57 months. Recurrence rates 
after 12 months post-treatment are included here; later time points will be reported separately. 
After degreasing and carefully removing scabs, crusts, and exophytic tumour material, either 
BF-200 ALA gel or MAL cream was administered to the lesions at about 1 mm thickness.  
Subsequently, an occlusive light-tight dressing was placed over the target lesions for the 
entire incubation period (3 h ± 10 min). Thereafter, remnant gel or cream was wiped off and 
illumination of the target lesion(s) was immediately performed.  
 
Efficacy assessment 
The clearance of individual lesions was assessed by visual inspection 4 and 12 weeks after 
treatments. The primary efficacy parameter was the overall patient complete response rate 12 
weeks after the last PDT defined as the complete clearance of all treated lesions. Subgroup 
analyses and analyses of secondary efficacy parameters (lesion complete response 12 weeks 
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after the last PDT, patient complete response rate 12 weeks after PDT-2) were performed 
according to BCC baseline characteristics.  
Cosmetic outcome was determined by the investigator according to skin quality parameters, 
as described by Reinhold et al.
 30
. Patient satisfaction was assessed 12 weeks after the last 
PDT using a 4-point scale from very good to impaired. 
 
Safety and tolerability assessment 
Local adverse reactions at the application site were documented during and after PDT. 
Symptoms were classified into mild, moderate, and severe. Ranking of the subjective 
sensations pain, burning and itching was done by the patient. Pain during PDT was assessed 
with a numeric rating pain scale (NRPS) ranging from 0 (no pain at all) to 10 (worst possible 
pain). For the overall adverse event (AE) assessment these data were transferred to a 4-point 
severity scale (0 = none, >0-3 = mild, 4-7 = moderate, 8-10 = severe). Treatment-emergent 
AEs (TEAEs) were defined as all AEs with onset or worsening after first treatment with 
randomized medication until the end of the clinical observation period. Serious adverse 
events (SAEs) were documented and evaluated throughout the study.  
 
Statistical analysis 
The method of Farrington and Manning for testing non-inferiority of differences of 
proportions was used to test the primary hypothesis on a significance level of 2.5% (one-
sided). A sample size of 115 evaluable patients per treatment group ensured a power of ≥90% 
for evaluation of the primary efficacy parameter, the overall patient complete response rate 
12 weeks after the last PDT. This estimate was based on an expected response rate of 87% in 
each treatment arm and a non-inferiority margin of Δ = -15. Analysis was performed on the 
per-protocol set; the full analysis set (FAS) was presented as supportive analyses. All other 
data were analysed descriptively and in an exploratory way. 
 
Recurrence rates during FU were calculated for patients and for lesions with a complete 
response 12 weeks after the last PDT according to the primary and secondary efficacy 
variables. To determine the probability of remaining cleared up to a particular FU visit, life 
tables were calculated for patients and lesions by multiplying the recurrence rate at FU (Pi) 
with the initial clearance rate (Pi*CR or Pi*RCL) as previously described 
31
.  
 
Results  
Patients 
The clinical observation period took place from Jan 2014 to Nov 2015; 1-year FU was 
completed in Aug 2016. Of 281 randomized patients (138 patients to BF-200 ALA gel and 
143 patients to MAL cream), 19 patients prematurely discontinued the clinical part of the 
study. A flow chart of the disposition of patients is presented in Figure 1. All patients were 
Caucasian. Patient and lesion characteristics are summarized in Table 1.  
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Efficacy  
Overall Patient Complete Response Rate 
At 12 weeks after the last PDT, 93.4% (n=113) of patients in the BF-200 ALA group showed 
complete clearance of all BCC lesions compared to 91.8% (n=101) in the MAL group (Table 
2). The non-inferiority test revealed a difference of means of 1.6 with a one-sided 97.5% CI 
of -6.5% (p < 0.0001), thus demonstrating statistical non-inferiority of BF-200 ALA gel 
compared to MAL cream for the primary efficacy parameter. The robustness of the results 
was confirmed by repeating the analyses on the FAS, which displayed a difference in efficacy 
of 5.2 (97.5% CI: -3.3; p < 0.0001) with 89.9% (n=124) of the patients in the BF-200 ALA 
group and 84.6% (n=121) in the MAL group showing complete clearance. More than half of 
the patients were already completely cleared 12 weeks after PDT-2 in both treatment arms: 
57.9% in the BF-200 ALA group and 56.4% in the MAL group, respectively, with 
overlapping 95% CIs.  
With respect to patients suffering from sBCC only, 94.7% in the BF-200 ALA, and 96.4% in 
the MAL group, respectively, showed complete clearance 12 weeks after the last treatment. 
Patients with nBCC only displayed clearance rates of 85.7% in the BF-200 ALA, and 76.2% 
in the MAL group, respectively (Table 2). Further subgroup analyses revealed clearance rates 
of 91.8% for the BF-200 ALA group and 92.6% for the MAL group with only 1 BCC lesion, 
whereas clearance rates for patients with 2 or more lesions were 100% and 87.5%, 
respectively. Differences between treatments are displayed in Figure 2. 
One year after the last treatment (FU2) overall patient relapse occurred to a similar extent in 
both groups (8.4% for BF-200-ALA, 8.5% for MAL). Thus, of the full responders 12 weeks 
after the last PDT >91% remained fully cleared 12 months after PDT. In patients with sBCC 
only, the recurrence rate dropped to 6.9% for BF-200 ALA and to 8.0% for MAL, 
respectively. A larger difference was observed for patients with nBCC only, with 6.7% of the 
BF-200 ALA-, and 14.3% of the MAL-treated patients, respectively, relapsing within 12 
months (Table 2).  
Considering the still cleared patients at 1-year FU, the initial difference of 1.6% between both 
treatments was maintained due to the low recurrence rates. From the perspective of pre-
treatment an overall patient clearance (Pi*CR) of 85.8% was calculated for the BF-200 ALA 
group compared to 84.4% for the MAL group. These values spread to 88.3% versus 89.0% 
for sBCC, and to 81.0% versus 66.3% for nBCC in the BF-200 ALA and MAL groups, 
respectively, at 1-year FU (Table 2). 
Lesion Complete Response Rate 
The rate of completely cleared individual lesions assessed 12 weeks after the last PDT was 
94.6% (n=148) in the BF-200 ALA, and 92.9% (n=127) in the MAL group. Subgroup 
analyses revealed numerical differences in lesion complete response rates when comparing 
BF-200 ALA with MAL treatment of sBCC (95.8% versus 96.9%), of nBCC (89.3% versus 
78.6%), on face/scalp (82.4% versus 70.6%), on neck/trunk (97.9% versus 96.6%), and on 
extremities (91.2% versus 95.7%), respectively, but without statistical significance (Table 3). 
It is of note that there is some variation in the group sizes per treatment area as recruitment 
was not stratified for this parameter (Table 1).  
From the cleared lesions observed during FU, 6.7% in the BF-200 ALA-, and 8.2% in the 
MAL group, respectively, relapsed within 12 months after the last PDT. Thus, of all lesions 
that had been clinically assessed as fully cleared after 3 months, 93.3% treated with BF-200 
ALA and 91.8% treated with MAL were still clear at this time point. Regarding the sBCC 
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and nBCC lesions, 5.4% and 9.1% of lesions in the BF-200 ALA groups, respectively, and 
7.9% and 10.0% in the MAL group, respectively, relapsed within 1 year after the last PDT. 
One-year recurrence rates for the different locations were 7.7% (face/scalp), 6.7% 
(neck/trunk), and 6.5% (extremities) in the BF-200 ALA group. The corresponding values in 
the MAL group were 18.2% (face/scalp), 7.6% (neck/trunk), and 5.0% (extremities) (Table 
3).  
Relative to the lesion number at baseline, the estimate for lesions to be cleared 1 year after 
the last treatment (Pi*RLC) was 88.4% in the BF-200 ALA, and 85.6% in the MAL group, 
respectively. For the main BCC subtypes, sBCC and nBCC, the estimates were 90.7% and 
81.9% in the BF-200 ALA group compared to 89.5% and 71.3% in the MAL group, 
respectively. Thus, the initial proportion between the efficacies are maintained throughout the 
FU supporting an advantage for BF-200 ALA especially in nBCC treatment (Table 3). 
Cosmetic Outcome 
The overall cosmetic outcome was rated as very good or good by 60% of the patients treated 
with BF-200 ALA and by 48.6% of the patients treated with MAL (excluding those patients 
without skin quality impairment at baseline) 12 weeks after the last PDT (Table 4). The 
favourable assessment of very good or good increased during FU to 73.2% in BF-200 ALA-
treated patients and to 68.4% in MAL-treated patients 1 year after the last PDT, respectively.  
Patient satisfaction 
The vast majority of patients in both groups rated their satisfaction as “very good or good” 
(87% of patients in the BF-200 ALA group and 86% of patients in the MAL group). This 
high satisfaction was maintained during the 1-year FU. 97.2% of BF-200 ALA-, and 99.0% 
of MAL-treated patients were still satisfied with PDT. No patient assessed the outcome as 
impaired at either time point. 
 
Safety and Tolerability 
Frequencies and severity of TEAEs were within the range as expected with a BCC population 
of mainly elderly patients, the nature of the underlying disease, and the known safety profile 
of PDT with BF-200 ALA gel and MAL cream, which is related to the mode of action (Table 
5). Frequencies were comparable between the groups and revealed no statistically significant 
differences. The most commonly reported TEAEs in both groups were local reactions at the 
application site (pain, erythema, pruritus, and oedema). The majority of related TEAEs were 
of mild to moderate intensity. Ten (3.6%) patients reported serious TEAEs during the clinical 
study part, which were all assessed as not related to study medication. Only four patients 
discontinued the study prematurely (Table 5). Local pain (NRPS) experienced during PDT 
was assessed for each PDT session and showed similar values for both treatments (Table 6).   
   
Discussion 
Recent guidelines for BCC treatment discuss the choice of useful therapies based on the 
prognosis rather than on the clinical/histological subtype. For non-aggressive BCC displaying 
good to intermediate prognosis, PDT is regarded as a highly appropriate treatment option, 
providing high efficacy and favourable cosmetic outcome without significant functional 
constraints 
5,8,9
. 
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In the presented study, high overall response rates of >90% were obtained for both 
medications 12 weeks after the last PDT, with a patient complete response rate of 93.4% for 
BF-200 ALA versus 91.8% for MAL. Even after the first PDT cycle considerably more than 
50% of the patients were clinically clear of BCC in both groups. Statistical analysis revealed 
that BF-200 ALA gel was non-inferior compared to the registered MAL cream.  
The current study was designed to show non-inferiority of BF-200 ALA in comparison to 
MAL. However, superiority of BF-200 ALA had previously been demonstrated in a phase III 
trial treating actinic keratosis randomizing 571 patients 
32
. In particular, the efficacy for 
thicker lesions or more difficult-to-treat lesions on the scalp was higher with BF-200 ALA 
21,32
. In the present trial, similar findings were seen for nBCC lesions, for whom numerical 
higher proportion of response was revealed with BF-200 ALA (89.3%) than with MAL 
(78.6%) which was maintained during the 1-year FU period. Previous results reported by 
Rhodes et al. 
23
 showed high efficacies of MAL-PDT in the treatment of nBCC when 
compared to surgery (91% vs 96%, p=0.15). The differences for MAL may be due to 
different lesion preparations in the studies. Lower efficacy rates for nBCC were also 
described in the survey of Peng et al. 
33
 using extemporaneous ALA formulations. Based on 
12 ALA-PDT studies with 208 lesions they achieved a weighted average complete response 
of 53%. The high efficacy observed for BF-200 ALA in the present study is presumed to be 
due to enhanced skin penetration of this formulation.  
For sBCC lesions where skin penetration is less relevant, both medications displayed very 
similar efficacies (≥95%). These results exceed the weighted clearance rate of 87% calculated 
on the basis of 12 sBCC studies with 826 lesions treated with ALA-PDT 
33
. Again, this may 
depend on the different formulations and treatment protocols 
29
. In a previous study 
comparing MAL-PDT to surgery on sBCC, non-inferiority was demonstrated for MAL-PDT 
with clearance rates of 92.2% (MAL) vs 99.2% (surgery) 
20
. A meta-analysis of 28 studies 
including various topical treatments resulted in clearance rates of 79% for MAL-PDT 
compared to 86.2% for imiquimod and indicated tumour free 1-year survival rates of 84% 
and 87.3%, respectively 
11
. An additional study by Arits et al. 
34
 reported clearance rates for 
sBCC of 90.0% with imiquimod, 87.9% with 5-fluorouracil, and 84.2% with MAL after 3 
months. In this study, only one PDT cycle was applied for MAL treatment, which is not in 
agreement with its label, while all other drugs were used according to their approved 
posology. However, after 12 months, the overall estimate of treatment success was calculated 
as 87.2%, 80.1%, and 72.5% for imiquimod, 5-fluorouracil, and MAL, respectively. In the 
present study, corresponding estimates were 88.3% for BF-200 ALA gel and 89.0% for MAL 
cream, respectively (Table 2). As patients will be followed-up for another 4 years, future 
recurrence rates will provide additional insight into the efficacy of BF-200 ALA-PDT. 
Overall, high efficacy rates and low recurrence rates in the treatment of non-aggressive BCC, 
were achieved with BF-200 ALA- and MAL-PDT. The local adverse events observed in this 
study are well known for PDT and caused by the underlying mode of action. No difference in 
adverse events became apparent between both treatments. Several European guidelines have 
rated PDT in the categories Quality of Evidence: I, and Strength of Recommendation: A (for 
sBCC) or B (for nBCC) 
5,8,35
. The present study reinforces the high ranking of PDT in the 
treatment of BCC. With BF-200 ALA, an excellent alternative for thin non-aggressive BCC 
is provided.  
  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Acknowledgement 
The authors are grateful to the staff of the participating clinical study centres for patient 
recruitment and treatment. We are also indebted to the patients involved in this trial. 
We gratefully acknowledge the assistance of Miriam Kremser and Ben Novak in the 
preparation of the manuscript and would like to thank the BCC Project team at Accovion 
GmbH (Frankfurt, Germany), and Aylin Amrani-Hanchi and Anika Hunfeld at Biofrontera 
for excellent support during the clinical trial. 
 
References 
 
1.  LeBoit PE, Burg G, Weedon D, Sarasin A (Eds.). World Health Organization 
Classification of Tumours. Pathology and Genetics of Skin Tumours. Lyon: IARC Press, 
2006. 
2.  Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: 
presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23(3-4): 389-402. 
3.  Trakatelli M, Ulrich C, del M, V, et al. Epidemiology of nonmelanoma skin cancer 
(NMSC) in Europe: accurate and comparable data are needed for effective public health 
monitoring and interventions. Br J Dermatol 2007; 156 Suppl 3: 1-7. 
4.  Athas WF, Hunt WC, Key CR. Changes in nonmelanoma skin cancer incidence between 
1977-1978 and 1998-1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 
2003; 12(10): 1105-8. 
5.  Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell 
carcinoma management. Eur J Dermatol 2014; 24(3): 312-29. 
6.  Flohil SC, de Vries E, Neumann HA, et al. Incidence, prevalence and future trends of 
primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91(1): 24-30. 
7.  Perera E, Gnaneswaran N, Staines C, et al. Incidence and prevalence of non-melanoma 
skin cancer in Australia: A systematic review. Australas J Dermatol 2015; 56(4): 258-67. 
8.  Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell 
carcinoma. Br J Dermatol 2008; 159(1): 35-48. 
9.  Dandurand M, Petit T, Martel P, et al. Management of basal cell carcinoma in adults 
Clinical practice guidelines. Eur J Dermatol 2006; 16(4): 394-401. 
10.  Patel RV, Frankel A, Goldenberg G. An update on nonmelanoma skin cancer. J Clin 
Aesthet Dermatol 2011; 4(2): 20-7. 
11.  Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment 
success after treatment of primary superficial basal cell carcinoma: a systematic review and 
meta-analysis of randomized and non-randomized trials. Br J Dermatol 2012; 167(4): 733-
56. 
12.  Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple 
patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137(3): 319-24. 
13.  Blume JE, Oseroff AR. Aminolevulinic acid photodynamic therapy for skin cancers. 
Dermatol Clin 2007; 25(1): 5-14. 
14.  Roozeboom MH, Aardoom MA, Nelemans PJ, et al. Fractionated 5-aminolevulinic acid 
photodynamic therapy after partial debulking versus surgical excision for nodular basal cell 
carcinoma: A randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol 
2013; 69(2): 280-7. 
15.  Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of 
basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144(4): 832-
40. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
16.  Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, 
prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for 
nodular basal cell carcinoma. Arch Dermatol 2007; 143(9): 1131-6. 
17.  Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-
photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: 
results of a randomized controlled trial. Br J Dermatol 2008; 159(4): 864-70. 
18.  Kuijpers DI, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl 
aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell 
carcinoma. J Drugs Dermatol 2006; 5(7): 642-5. 
19.  Szeimies RM. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. 
Dermatol Clin 2007; 25(1): 89-94. 
20.  Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl 
aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma 
(8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22(11): 1302-
11. 
21.  Maisch T, Santarelli F, Schreml S, et al. Fluorescence induction of protoporphyrin IX by 
a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness 
ex vivo skin model. Exp Dermatol 2010; 19(8): e302-e5. 
22.  Schmitz L, Novak B, Hoeh AK, et al. Epidermal penetration and protoporphyrin IX 
formation of two different 5-aminolevulinic acid formulations in ex vivo human skin. 
Photodiagnosis Photodyn Ther 2016; 14: 40-6. 
23.  Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl 
aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter 
randomized prospective trial. Arch Dermatol 2004; 140(1): 17-23. 
24.  Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate 
photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year 
randomized trial. Eur J Dermatol 2008; 18(5): 547-53. 
25.  Foley P. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. J 
Dermatolog Treat 2003; 14 Suppl 3: 15-22. 
26.  Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous 
protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 
1990; 6(1-2): 143-8. 
27.  Schulten R, Novak B, Schmitz B, Lubbert H. Comparison of the uptake of 5-
aminolevulinic acid and its methyl ester in keratinocytes and skin. Naunyn Schmiedebergs 
Arch Pharmacol 2012; 385: 969–79. 
28.  Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA 
Cancer J Clin 2011; 61(4): 250-81. 
29.  Hurlimann AF, Hanggi G, Panizzon RG. Photodynamic therapy of superficial basal cell 
carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 1998; 
197(3): 248-54. 
30.  Reinhold U, Dirschka T, Ostendorf R, et al. A randomized, double-blind, phase III, 
multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R)) ) vs. 
placebo in the field-directed treatment of mild-to-moderate actinic keratosis with 
photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. Br J Dermatol 2016; 
175(4): 696-705. 
31.  Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two 
prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 
ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 
168(4): 825-36. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
32.  Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for 
the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase 
III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J 
Dermatol 2012; 166(1): 137-46. 
33.  Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. 
Clinical research and future challenges. Cancer 1997; 79(12): 2282-308. 
34.  Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod 
versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, 
non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14(7): 647-54. 
35.  Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical 
photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, 
Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27(5): 536-44. 
 
 
 
Figures and Tables 
 
Figure legends: 
 
 
Figure 1: Flow chart of patient disposition in clinical study part 
*Initially, it was considered an exclusion criterion if – besides an eligible BCC – subjects had 
non-eligible BCC (all confirmed by biopsy), which resulted in a high amount of screening 
failures. In the course of the study, the protocol was amended such that individuals with at 
least one biopsy-proven, eligible BCC could be included if the distance to a non-eligible 
lesion was more than 10 cm. The protocol amendment was not expected to influence the 
composition of the enrolled patient population. 
 
 
 
Figure 2: Treatment efficacy  
Overall patient complete response rates and subgroup analyses for the per-protocol set. A 
patient was considered as complete responder if all treated lesions were cleared 12 weeks 
after the last PDT. Error bars represent one-sided 97.5% confidence intervals of the 
difference between BF-200 ALA and MAL treatment. The blue dashed line at -15 = Δ 
indicates the non-inferiority margin for the primary efficacy variable; the blue region to the 
right of -15 = Δ indicates the zone of non-inferiority. 
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 Table 1: Summary of patient and BCC lesion characteristics before treatment  
Variable 
MAL cream 
N=110 
BF-200 ALA gel 
N=121 
Sex, n (%)   
Male 55 (50.0) 76 (62.8) 
Female 55 (50.0) 45 (37.2) 
Age (years)   
Mean (SD) 66.5 (11.53) 67.3 (11.59) 
Fitzpatrick Skin Type Score, n (%)   
I-III 98 (89.1) 109 (90.1) 
IV-VI 12 (10.9) 12 (9.9) 
BCC lesions at baseline 127 148 
BCC lesions at baseline per patient,  
Mean (SD) 
1.2 (0.39) 1.2 (0.49) 
No of BCC lesions at baseline per patient (%)   
n = 1 94 (85.5) 98 (81.0) 
n ≥ 2 16 (14.5) 23 (19.0) 
BCC subtype*, n (%)   
nBCC only 21 (19.1) 21 (17.4) 
sBCC only 83 (75.5) 95 (78.5) 
Others 6 (5.5) 5 (4.1) 
Location of lesions, n (%)   
Face/scalp# 17 (13.6)  17 (11.5) 
Neck/trunk 87 (68.5) 97 (65.5) 
Extremities 23 (18.1) 34 (23.0) 
Thickness of BCC lesions overall (mm),  
Mean (SD) 
0.46 (0.36) 0.41 (0.32) 
BCC: basal cell carcinoma; Max: maximum; Min: minimum; N: number of patients in a treatment group; n: number of 
patients, nBCC: nodular BCC; sBCC: superficial BCC, SD: standard deviation.  
* Patient-based 
# Only one lesion was located on the scalp. 
Data presented for the per-protocol set. 
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Table 2:  Patient clearance and recurrence rates  
 MAL cream BF-200 ALA gel 
Subgroup/ 
Assessment time 
point after last 
PDT 
Completely 
cleared 
 n/N (%) 
Recurrent 
 n (%) 
Pi 
 [%] 
Pi*CR 
[%] 
Completely 
cleared 
 n/N (%) 
Recurrent 
 n (%) 
Pi  
[%] 
Pi*CR 
[%] 
Overall                 
EOS (12 weeks) 101/110 
(91.8) 
na 100 91.8 113/121 
(93.4) 
na 100 93.4 
95% CI 84.6 – 96.0    87.0 – 96.9    
FU2 (12 months) 86/94* (91.5) 8 (8.5) 91.9 84.4 98/107* 
(91.6) 
9 (8.4) 91.9 85.8 
95% CI 83.4 – 96.0 4.0 – 16.6   84.2 – 95.8 4.2 – 15.8   
with sBCC only               
EOS (12 weeks) 80/83 (96.4) na 100 96.4 90/95 (94.7) na 100 94.7 
95% CI 89.1 – 99.1    87.6 – 98.0    
FU2 (12 months) 69/75* (92.0) 6 (8.0) 92.3 89.0 81/87* (93.1) 6 (6.9) 93.3 88.3 
95% CI 82.8 – 96.7 3.3 – 17.2   85.0 – 97.2 2.8 – 15.0   
with nBCC only          
EOS (12 weeks) 16/21 (76.2) na 100 76.2 18/21 (85.7) na 100 85.7 
95% CI 52.5 – 90.0    62.6 – 96.2    
FU2 (12 months) 12/14* (85.7) 2 (14.3) 87.1 66.3 14/15* (93.3) 1 (6.7) 94.4 81.0 
95% CI 56.2 – 97.5 2.5 – 43.8   66.0 – 99.7 0.3 – 34.0   
BCC: basal cell carcinoma; CI: confidence interval; EOS: end of clinical study, 12 weeks after last PDT; FU2: Follow-up 2, 
12 months after last treatment; N:  total number of patients with assessment; n: number of patients; na: not applicable; 
nBCC: nodular BCC; PDT: photodynamic therapy; Pi: Probability of patients remaining fully cleared until current visit (in 
percentage); Pi*CR: Estimated rate of patient clearance at current visit related to number of patients pre-treatment (in 
percentage); sBCC: superficial BCC. 
* Complete responders 12 weeks after last PDT with data at 1 year follow-up 
Data presented for the per-protocol set. 
 
 
Table 3:  Lesion clearance and recurrence rates  
  MAL cream   BF-200 ALA gel 
Subgroup/ 
Assessment time 
point after last 
PDT 
Completely 
cleared 
 n/N (%) 
Recurrent 
 n (%) 
Pi 
(%) 
Pi*RLC 
(%) 
Completely 
cleared 
 n/N (%) 
Recurrent 
 n (%) 
Pi 
(%) 
Pi*RLC 
(%) 
Overall                 
EOS (12 weeks)                     118/127 
(92.9) 
na 100 92.9 140/148 
(94.6) 
na 100 94.6 
95% CI 86.6 – 96.5    89.3 – 97.5    
FU2 (12 months)                           101/110* 
(91.8) 
9 (8.2) 92.2 85.6 125/134* 
(93.3) 
9 (6.7) 93.5 88.4 
95% CI 84.6 – 96.0 4.0 – 15.4   87.3 – 96.7 3.3 – 12.7   
sBCC           
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EOS (12 weeks)                        95/98 (96.9) na 100 96.9 114/119 
(95.8) 
na 100 95.8 
95% CI 90.7 – 99.2    90.0 – 98.4    
FU2 (12 months)                         82/89* 
 (92.1) 
7 (7.9) 92.4 89.5 105/111* 
(94.6) 
6 (5.4) 94.7 90.7 
95% CI 83.9 – 96.5 3.5 – 16.1   88.1 – 97.6 2.2 – 11.9   
nBCC           
EOS (12 weeks)                        22/28 (78.6) na 100 78.6 25/28 (89.3) na 100 89.3 
95% CI 58.5 – 91.0    70.6 – 97.2    
FU2 (12 months)                          18/20*  
(90.0) 
2 (10.0) 90.7 71.3 20/22*  
(90.9) 
2 (9.1) 91.7 81.9 
95% CI 66.9 – 98.2 1.8 – 33.1   69.4 – 98.4 1.6 – 30.6   
BCC face/scalp
#
         
EOS (12 weeks)                       12/17 (70.6) na 100 70.6 14/17 (82.4) na 100 82.4 
95% CI 44.0 – 88.6    55.8 – 95.3    
FU2 (12 months)                          9/11* (81.8) 2 (18.2) 82.6 58.3 12/13* (92.3) 1 (7.7) 92.6 76.3 
95% CI 47.8 – 96.8 3.2 – 52.2   62.1 – 99.6 0.4 – 37.9   
BCC neck/trunk         
EOS (12 weeks)                        84/87 (96.6) na 100 96.6 95/97 (97.9) na 100 97.9 
95% CI 89.5 – 99.1    92.0 – 99.6    
FU2 (12 months)                       73/79* 
(92.4) 
6 (7.6) 92.7 89.5 84/90* (93.3) 6 (6.7) 93.6 91.7 
95% CI 83.6 – 96.9 3.1 – 16.4   85.5 – 97.3 2.7 – 14.5   
BCC extremities         
EOS (12 weeks)                         22/23 (95.7) na 100 95.7 31/34 (91.2) na 100 91.2 
95% CI 76.0 – 99.8    75.2 – 97.7    
FU2 (12 months)                         19/20* 
(95.0) 
1 (5.0) 95.3 91.2 29/31* (93.5) 2 (6.5) 93.5 85.3 
95% CI  73.1 – 99.7 0.3 – 26.9   77.2 – 98.9 1.1 – 22.8   
BCC: basal cell carcinoma; CI: confidence interval; EOS: end of clinical study, 12 weeks after last PDT; FU2: Follow-up 2, 
12 months after last treatment; N:  total number of patients with assessment; n: number of patients; na: not applicable; 
nBCC: nodular BCC; PDT: photodynamic therapy; Pi: Probability of lesions remaining cleared up to current visit (in 
percentage); Pi*RLC: Estimated rate of lesion clearance at current visit related to number of lesions pre-treatment (in 
percentage); sBCC: superficial BCC. 
* BCC lesions cleared 12 weeks after last PDT with data at 1 year follow-up 
# Only one lesion was located on the scalp. 
Data presented for the per-protocol set. 
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Table 4: Cosmetic outcome 12 weeks after the last PDT and 1 year follow-up  
(patients with baseline evaluation “none”* were excluded) 
 MAL cream n (%) BF-200 ALA gel n (%) 
 
EOS 
N=74* 
1yFUP 
N=57*
#
 
EOS  
N=70* 
1yFUP  
N=56*
#
 
Very good, n (%) 16 (21.6) 17 (29.8) 28 (40.0) 20 (35.7) 
95% CI 13.2 – 33.0 18.8 – 43.6 28.7 – 52.4 23.7 – 49.7 
Good, n (%) 20 (27.0) 22 (38.6) 14 (20.0) 21 (37.5) 
95% CI 17.7 – 38.8 26.3 – 52.4 11.7 – 31.6 25.2 – 51.5 
Satisfactory, n (%) 24 (32.4) 8 (14.0) 16 (22.9) 8 (14.3) 
95% CI 22.3 – 44.4 6.7 – 26.3 14.0 – 34.7 6.8 – 26.8 
Unsatisfactory, n (%) 9 (12.2) 6 (10.5) 8 (11.4) 2 (3.6) 
95% CI 6.1 – 22.3 4.4 – 22.2 5.4 – 21.8 0.6 – 13.4 
Impaired, n (%) 5 (6.8) 4 (7.0) 4 (5.7) 5 (8.9) 
95% CI 2.5 – 15.7 2.3 – 17.8 1.8 – 14.7 3.3 – 20.4 
1yFUP: follow-up 12 months after last PDT; CI: confidence interval; EOS: end of clinical study (12 weeks after last PDT); 
N:  total number of patients with assessments at baseline and at respective follow-up visit; n: number of patients with 
respective improvement from baseline; PDT: photodynamic therapy. 
Cosmetic outcome was calculated on the base of skin quality assessment 30. Parameters (skin surface, pigmentation, degree 
of scarring, and atrophy) were rated on a 4-point scale from none to severe at baseline, at the end of the clinical observation 
period 12 weeks after the last PDT, and during follow-up (FU).  
* Patients lacking compromised skin at baseline were excluded. 
# Only complete responders are considered and patients with recurrent BCC lesions are excluded. 
Data presented for the per-protocol set. 
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Table 5 Overview of TEAEs  
TEAE category 
Number (%) of patients 
MAL cream 
N=143 
BF-200 ALA gel 
N=138 
Patients with TEAEs 143  (100.0) 138 (100) 
Patients with relateda TEAEs 143  (100.0) 138 (100) 
Patients with serious TEAEs 7 (4.9) 3 (2.2) 
Patients with relateda serious TEAEs 0 – 0 – 
Patients with TEAEs leading to death  1 (0.7) 0 – 
Patients with relateda TEAEs leading to death 0 – 0 – 
Patients with TEAEs leading to study withdrawal  2 (1.4) 1 (0.7) 
Patients with relateda TEAEs leading to study withdrawal 1 (0.7) 1 (0.7) 
Patients with TEAEs rated as local skin reaction 130 (90.9) 122 (88.4) 
Patients with relateda TEAEs rated as local skin reaction 130 (90.9) 121 (87.7) 
Patients with TEAEs rated as discomfort 143 (100.0) 136 (98.6) 
Patients with relateda TEAEs rated as discomfort 143 (100.0) 136 (98.6) 
Patients with pain 143 (100.0) 134 (97.1) 
Patients with pain considered relateda to study treatment 143 (100.0) 134 (97.1) 
N= number of patients in a treatment group; TEAE= treatment emerged adverse event. 
a Considered possibly, probably, or definitely related to study treatment. 
Data comprised of TEAEs until 12 weeks after the last PDT.  
Data presented for the safety population. 
 
 
 
 
 Table 6: Maximal pain sensation during PDT 
  
  PDT-1 PDT-2 PDT-3 PDT-4 
MAL cream  N 143 142 61 60 
 Mean (SD) 3.6 (2.22) 4.1 (2.66) 2.5 (2.23) 2.9 (2.75) 
BF-200 ALA gel N 138 138 54 55 
 Mean (SD) 3.7 (2.42) 4.5 (2.69) 2.8 (2.55) 3.9 (2.97) 
N= number of patients in a treatment group; PDT: photodynamic therapy; SD: Standard deviation. 
Data present the means and SD of an 11-point numeric rating pain scale (NRPS) ranging from 0 (no pain at all) to 10 (worst 
possible pain) according to the patients assessment.  In order to record pain experienced by the patients during the treatment, 
the PDT was to be started without measures to relieve pain. Potential pain management afterwards included physical cooling 
measures, reduction of light intensity to the expense of longer exposure times, or slight analgesia. 
Data presented for the safety population. 
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